Trial Profile
An Open-label, Single Sequence Crossover, Study Investigating the Influence of Secukinumab Treatment on the Pharmacokinetics of Midazolam as a CYP3A4 Substrate in Patients With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Midazolam
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 22 Jun 2019 Results assessing effect of secukinumab on the pharmacokinetics of midazolam published in the Clinical Pharmacology and Therapeutics.
- 24 May 2017 Status changed from active, no longer recruiting to completed.
- 11 Jul 2016 Status changed from recruiting to active, no longer recruiting.